Physician profile
Matthew D Hammit
NPI 1235134362
$54,203.42
in general payments reported to CMS, 2019-2025
14 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.60 · 2020: $15.19 · 2021: $1,331 · 2022: $46K · 2023: $5,169 · 2024: $1,325 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $6,194 · Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $6,193.84 |
| Food and Beverage | $518.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $52,164.76 | 2022-2024 | Avenger Radial Head, +4 Stems |
| Medinc of Texas | $1,200.00 | 2021 | |
| Treace Medical Concepts, INC. | $142.71 | 2022-2025 | |
| Encore Medical, LP | $135.60 | 2023 | Djo Surgical |
| Horizon Therapeutics Plc | $118.13 | 2021 | |
| Stryker Corporation | $99.03 | 2022-2025 | Augment Injectable, Valor |
| Medtronic USA, INC. | $61.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $49.67 | 2025 | Euflexxa |
| Revance Therapeutics, INC. | $49.00 | 2025 | Daxxify |
| Mindray Ds USA, INC. | $47.89 | 2024 | Te X, Te7 Max |
| Alafair Biosciences, INC. | $40.38 | 2022 | |
| Biotissue Holdings INC. | $35.47 | 2025 | |
| Depuy Synthes Sales INC. | $30.74 | 2025 | Orthocord |
| Allergan, INC. | $28.44 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hammit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.